IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC

NCT05059470 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped \<75% participant accrual

Conditions

Thyroid

Interventions

DRUG: Pembrolizumab

Sponsor

M.D. Anderson Cancer Center